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ABSTRACT  
A 60 year old Nigerian man, who had lived in Europe for 30 years but had 
returned home frequently, presented with weakness of the right frontalis and 
right ulnar nerve palsy with no skin lesions. Neurophysiology showed a 
generalised neuropathy with demyelinating features. Blood tests were positive 
for HIV with a normal CD4 count. Nerve thickening was subsequently 
demonstrated both clinically and on MRI. Nerve biopsy showed chronic 
endoneuritis and perineuritis (indicative of leprosy) with no mycobacteria 
seen. His neuropathy continued to deteriorate (lepra reaction) prior to starting 
treatment with WHO multi drug therapy, highly active antiretroviral therapy 
and steroids. Ten new cases of leprosy are diagnosed annually in the UK. 
Coinfection with HIV is rare but paradoxically does not usually adversely 
affect the outcome of leprosy or change treatment. However, permanent 
nerve damage in leprosy is common despite optimal therapy. Leprosy should 
be considered in patients from endemic areas who present with mononeuritis 
multiplex. 
 
 
KEY LEARNING POINTS 
1. Leprosy patients are regularly seen in the UK with about ten new cases a year 
and should be suspected in every patient with mononeuritis multiplex from an 
endemic area. 
2. Pure neural leprosy (5% of cases) can be difficult to diagnose due to lack of 
skin lesions and nerve biopsy is needed for diagnosis. 
3. Deterioration before and after starting treatment (lepra reaction) is well 
recognised and patients require steroid treatment. 
4. Even with modern treatments about 50% of patients will have major persistent 
nerve damage. 
5. Paradoxically coinfection with HIV does not adversely affect the natural 
history of leprosy. 
 
 
 
 
 
 
CASE  
A 60 year old right handed Nigerian man, with type 2 diabetes for 15 years, 
presented with right sided facial weakness. Direct questioning revealed 12 months of 
progressive numbness in arms, legs and face.  On examination he had right sided 
facial weakness mainly affecting frontalis and a right sided ulnar nerve palsy. His 
biceps and supinator reflexes were present but triceps and lower limb reflexes were 
absent. His plantar response was mute. He had lived in Europe for over 30 years 
and returned to Nigeria several times a year. 
He was found to be HIV positive with CD4 count 410 cells/mm3, (normal 400-600 
cells/mm3), CD8 count 158cells/mm3 (normal 200-800 cells/mm3) and viral load 
130,000 copies/mL (normal 0 copies/mL). Syphilis serology was negative. 
Cerebrospinal fluid examination was unremarkable with a white cell count of 1 
cell/µL, protein 410mg/L and paired oligoclonal bands in both serum and CSF, no 
atypical cells on cytology, no organisms in culture or on Gram stain and negative 
viral PCR. 
He had neurophysiology studies (summarised in Table 1) which showed a rapidly 
progressive multifocal mixed sensory and motor neuropathy with evidence of 
demyelination and axonal loss. Motor conduction velocities were 29-40m/s.  All 
sensory nerve active potentials were absent. Blink reflexes confirmed bilateral facial 
nerve involvement with marked slowing of the R1 components bilaterally to 9 and 
14ms (normal ≥30ms).  
Despite starting highly active antiretroviral therapy with Atripla (efavirenz, 
emtricitabine, and tenofovir) his neuropathy continued to deteriorate developing 
three months later bilateral hand weakness (Figure 1) and difficulty walking. Further 
examination revealed thickened peripheral nerves (bilateral ulnars, medians, right 
lateral popliteal and radial cutaneous nerves). There were no skin lesions. Repeat 
neurophysiology (Table 1) confirmed a new left ulnar palsy with more severe 
demyelinating features and secondary axonal changes. 1.5 Tesla MRI of limbs 
showed STIR hyperintensity and mild corresponding thickening and faint 
enhancement in T1w and post-contrast fat suppressed T1w  of median, ulnar, radial, 
sciatic, tibial and common peroneal nerves. 
The biopsy of the right ulnar nerve showed a severe chronic axonal neuropathy 
across the fascicles with a complete loss of myelinated fibres and better preservation 
of the unmyelinated fibres. The perineurium around one of the fascicles was 
concentrically thickened and fibrosed. There were infiltrates of histiocytes, T and B 
lymphocytes and occasional plasma cells. Occasional perivascular mononuclear 
cells were also seen in the epineurium and endoneurium. There was no evidence of 
demyelination, no signs of active vasculitis and no granulomata. The tinctorial 
histochemical stain for the M.leprae acid fast bacilli was negative (Figure 2).  
 
 
A clinical diagnosis of pure neural borderline tuberculoid leprosy with HIV coinfection 
was made on the basis of the grossly thickened nerves and the significant 
inflammatory changes on the nerve biopsy in a man from an endemic area for 
leprosy especially in the context of facial nerve involvement. 
He was treated with World Health Organization leprosy multidrug therapy with 
rifampicin and dapsone. For six months, prednisolone was also given as standard 
treatment for tuberculoid leprosy neuropathy to prevent further lepra reaction related 
deterioration. His neuropathy remained stable with no further disability after six 
months and is followed up both by infectious disease and neurology. 
 
DISCUSSION 
The initial diagnosis was felt to be HIV related Chronic Inflammatory Demyelinating 
Polyneuropathy (CIDP) but facial palsies are extremely uncommon in CIDP and 
diabetic neuropathies. Common causes of thickened nerves are CIDP, multifocal 
acquired demyelinating sensory and motor neuropathy, leprosy, amyloidosis, 
neurolymphomatosis and Charcot Marie Tooth disease  type 1. The clinical 
combination of peripheral nerve thickening and facial nerve involvement strongly 
pointed towards leprosy (also known as Hansen’s Disease)  (Table 2).  
Whilst bilateral symmetrical facial nerve palsies are common in Lyme disease, 
Sarcoidosis and Acute Inflammatory Demyelinating Polyradiculoneuropathy, the 
patchy and bilateral pattern of facial paralysis seen in this case is probably unique to 
leprosy. The branches are affected where they assume a superficial course, i.e.in 
the forehead over the zygomatic arch and the mandible as M.leprae grow at lower 
temperatures. The initial dysfunction is usually weakness of eye closure due to 
damage to the branches coursing over the zygoma and the orbital rim. Total facial 
paralysis is said not to occur even in advanced cases.  
Leprosy patients are regularly seen in the UK.[1] Since it became a notifiable 
disease in 1951, there have been 1533 cases, approximately 10 per year. Most 
commonly patients originate from India, Sri Lanka, Pakistan and Nigeria. In endemic 
areas the diagnosis can be made clinically and classification on the number of skin 
lesions to allow treatment to be given without laboratory confirmation. 
Confirmation of the diagnosis beyond clinical features is not always straightforward. 
The three cardinal signs are: hypopigmented or reddish skin lesion(s) with sensory 
deficit; peripheral nerve thickening and demonstration of acid fast bacilli in the 
lesions. The classic neurophysiological pattern seen in leprosy is a sensory-motor 
asymmetric multiple neuropathy with focal demyelination and distal axonal 
impairment. In paucibacillary leprosy, at diagnosis 10% demyelinating (with 50% 
axonal; 40% no conduction) and at follow up one year after stopping treatment 55% 
demyelinating (9% axonal; 36% no conduction).[2] 
 
 
In non-endemic areas, such as the UK, it is usual to reach a conclusive diagnosis 
with either finding acid-fast bacilli (AFB) on microscopy (slit skin smears from skin 
lesions or ear lobes) in lepromatous cases or appropriate histological appearances 
(skin biopsy or in some cases, peripheral nerve biopsy) in tuberculoid cases as the 
effective immune response has eliminated the AFB.  
 
This patient was unusual in having pure neural leprosy (about 5% of all cases) which 
lack skin lesions usually requiring nerve biopsy.  M.leprae is only detected in ~25% 
of tuberculoid case as the immune response has eliminated the bacteria leaving the 
inflammation of M. leprae DNA can be detected by PCR in ~50% of cases. Nerve 
neuropathology can aid the diagnosis with 4 categories: (i) confirmed with 
inflammatory infiltrates composed of AFB-loaded macrophages; (ii) highly probable 
with epithelioid granulomas in the absence of AFB; (iii) probable with inflammatory 
mononuclear cell infiltrate in nerve compartments, particularly endoneurium and 
perineurium (iv) possible with perineurial thickening and endoneurial fibrosis. In this 
case the nerve neuropathology was consistent with probable leprosy and AFB were 
not detected. 
Patients with leprosy are classified on a clinical spectrum ranging from high cell-
mediated to high humoral immunity (Table 3). The cell-mediated response 
eliminates or contains the M.leprae in granulomas, while the ineffective humoral 
response allows the proliferation of mycobacteria. World Health Organization 
recommended treatment is with multidrug therapy according to disease 
classification: Multibacillary disease with Rifampicin 600 mg monthly, Dapsone 100 
mg daily and Clofazimine 300 mg monthly and 50 mg daily for 12 months , 
paucibacillary disease with Rifampicin 600 mg monthly and Dapsone 100 mg daily. 
Prednisolone is often added to multidrug therapy to reduce prevent nerve damage 
because without it 30% of people with borderline disease can deteriorate when 
multidrug therapy is started as a result of a reversal reaction. This occurs as the 
result of a sudden shift toward the cell mediated pole from the borderline state and 
can lead to irreversible nerve damage. 
Recovery after treatment for leprosy neuropathy depends on the stage of disease at 
onset of treatment. In general, only 50% see functional improvement. Hence early 
diagnosis and treatment is important and long term rehabilitation strategies are 
necessary for many cases. 
Perhaps surprisingly leprosy infection is only subtly affected by HIV coinfection.[3] 
HIV rates are high in leprosy endemic areas and although the number of co-infected 
patients is not known they are likely to be increasing. In contrast with the interaction 
with M. tuberculosis and disease due to Mycobacterium avium complex, M. leprae 
does not increase susceptibility to HIV. This paradox is not fully understood but may 
be due to differences in incubation times, the biology and toxicity of M.leprae 
compared to M. tuberculosis.  As the clinical spectrum of leprosy depends on the 
host immunity (Table 3) and HIV principally affects host cell-mediated immune 
responses, it was predicted that co-infected patients would present with lepromatous 
disease but this is not the case. Co-infection with HIV does not alter the clinical 
features of leprosy. Leprosy in HIV-positive individuals is not shifted to the 
lepromatous pole nor does it develop more quickly. Response to treatment is 
unaffected.  
Borderline disease comprises the intermediate spectrum of clinical forms of leprosy 
that are often immunologically unstable, potentially leading to reactional states. 
Some evidence suggests that the frequency and type of reactions are altered by HIV 
coinfection.  Also, leprosy has been described as an immune reconstitution disease 
when HIV infection is treated with highly active antiretroviral therapy and the early 
rapid phase of immune reconstitution allows pre-existing infections to become 
clinically manifest or deteriorate typically as tuberculoid leprosy with type 1 leprosy 
reaction. 
We present a case of mononeuritis multiplex in a known diabetic who was found to 
also have HIV infection, The final diagnosis was leprosy demonstrating the 
importance of considering leprosy if the patient has been in a prevalent area even 
when, as in this case, other explanations of a neuropathy are present. Also it is vital 
to consider the pattern of neuropathy present as the pattern of facial paralysis seen 
here is unique to leprosy. Considering leprosy and HIV co-infection provides further 
stimulus to examine the role of immune dysregulation in both infectious and immune 
mediated neuropathies.   
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FIGURE LEGENDS 
 
Figure 1: Clinical pictures 
Bilateral hand wasting  
 
Figure 2: Dorsal ulnar nerve biopsy 
Around some of the fascicles (A) the perineurium (red arrow) shows marked 
concentric thickening and is infiltrated by inflammatory cells (the inset in A for a 
comparison shows thickness of the perineurium (green arrow) in a normal control 
nerve; the perineural thickness in the index and control fascicles is indicated with 
black lines). Mononuclear inflammatory cells with perivascular distribution are also 
present in the epineurium (blue arrow) and endoneurium (yellow arrow). Semi-thin 
resin preparation (B) shows a complete loss of myelinated fibres, whilst the axons 
(inset in B, immunostained for neurofilaments) highlights occasional remaining 
unmyelinated fibres. Immunotyping shows that the inflammatory infiltrate in the 
epineurium, perineurium and endoneurium is composed of a mixed population of 
CD68 positive macrophages (C) and CD3 positive T lymphocytes (D).   
Scale bar: 200µm in A, C and D; 40µm in B.  
 
 
 
 
 
 
 
 
 
 
Table 1:  Neurophysiology 
 
SENSORY 
SNAP – all 
nerves 
Absent 
MOTOR Distal Latency 
(ms) 
Amplitude (mV) Velocity 
(m/s) 
F response - 
distal latency 
(ms) Distal Proximal 
Mar Dec Mar Dec Mar Dec Mar Dec Mar Dec 
R. median  5.8 8.3 6.0 0.20 3.0   39   31 Absent  
L. median   5.9 5.7 0.5 0.50 0.7 0.5 29 25   Absent  
R. ulnar  Absent Absent                 
L. ulnar  3.5 6.9 11.0 0.50 7.0 0.4 40 19 32 Absent  
R. lateral 
popliteal 
3.7 4.7 1.7 0.40 1.2 0.4 34 29 60 Absent  
L. lateral 
popliteal  
5.0 4.0 8.0 3.30 5.0 2.5 39 37 59 55 
R. medial 
popliteal 
6.8 7.3 1.4 0.04 1.4   29   67   
L. medial 
popliteal  
6.8 5.8 0.5 0.20         74 Absent  
 
 
 
 
 
 
 
 
Table 2: Differential diagnosis of patient presenting with features of leprosy 
 Mononeuritis 
multiplex 
Bilateral facial palsy Thickened nerves 
Traumatic Multiple compression 
neuropathies 
  
Infective  Hepatitis, 
ParvovirusB19, Lyme, 
Leprosy, HIV 
Lyme, Leprosy, HIV, 
Tuberculous meningitis, 
brainstem encephalitis, 
syphilis 
Leprosy 
Hereditary Hereditary neuropathy 
with liability to pressure 
palsies 
 Charcot Marie Tooth 
disease type 
1,Refsum's disease 
Inflammatory Multifocal motor 
neuropathy with 
conduction block, 
Multifocal acquired 
demyelinating sensory 
and motor neuropathy, 
Vasculitis, Sarcoidosis, 
Sjogren 
Acute Inflammatory 
Demyelinating 
Polyradiculoneuropathy, 
Sarcoidosis 
Chronic Inflammatory 
Demyelinating 
Polyneuropathy, 
MADSAM 
CSF 
disorders 
 Idiopathic intracranial 
hypertension 
 
Metabolic Diabetes Diabetes  
Neoplastic Lymphoma, 
Paraneoplastic  
Meningioma, 
neurofibroma, malignant 
meningitis 
Perineuroma, 
Schwannoma, 
neurofibroma 
Nerve 
infiltrations 
Amyloidosis  Amyloidosis, 
Neurolymphomatosis 
 
 
 
 
 
 
Table 3: Clinical spectrum of Leprosy 
Clinical presentation of leprosy reflects the cell-mediated immune response of the 
host.  World Health Organization (WHO) classification defines either paucibacillary or 
multibacillary disease based on number of skin lesions. Ridley-Jopling classification 
creates a clinical spectrum of tuberculoid, borderline tuberculoid, borderline, 
borderline lepromatous, and lepromatous leprosy based on skin lesion type and 
bacterial load.  Tuberculoid leprosy: vigorous cell-mediated immune response 
eliminates or contains the mycobacteria in granulomas resulting in well-demarcated 
lesions containing few bacilli and surrounded by lymphocytes. Lepromatous leprosy: 
no effective cell-mediated immunity allows the proliferation of mycobacteria within 
and around foamy macrophages. 
 
  
 
 
 
 
WHO  Paucibacillary (1-5 skin 
lesions) 
Multibacillary (>5 skin lesions) 
Ridley-Jopling  Tuberculoid Borderline 
tuberculoid 
Borderline Borderline 
lepromatous 
Lepromatous 
Cell mediated 
immunity 
High                                                                                                           Low 
Type  Polar 
tuberculoid 
Borderline Polar 
lepromatous 
Skin lesions Single/few 
anaesthetic 
patches;well 
defined  
Many anaesthetic lesions  with indistinct 
borders 
Multiple  non-
anaesthetic 
symmetric 
patches  
Nerve lesions Asymmetric
al nerve 
enlargement 
proximal to 
skin lesion 
May produce most nerve damage and 
multiple nerves involved 
No neural lesions 
until late when 
bilateral 
symmetrical distal 
neuropathy 
Histopathology Granulomas
;  bacilli rare  
Range; variable presence of bacilli Foamy cells ; 
numerous bacilli  
Stability Stable Unstable – may develop reactions and 
new nerve damage 
Stable 
